Engflag

Bonemax

Quick links to important sections

Bonemax

Bonemax_DE

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bonemax

What is Bonemax?

Bonemax is a prescription-only medicine containing the active compound Alendronate sodium, which functions specifically as a potent bone resorption inhibitor. This compound is chemically synthesized and is formally classified as a bisphosphonate. The general purpose of this therapy is to support skeletal integrity and help maintain existing structural bone health.

Quick Facts

Property Description
Active ingredient Alendronate sodium (Alendronic acid)
Form Oral tablet, Oral solution
Pharmacological class Bisphosphonate (Bone Resorption Inhibitor)
General purpose Maintaining bone structure and mineral density
Origin Synthetic compound

Core Composition and Classification

Bonemax belongs to the bisphosphonate pharmacological class, distinguished as a nitrogen-containing diphosphonate compound. Its active ingredient, Alendronate sodium, which is the INN equivalent of Alendronic acid, is a synthetic compound designed as an analog of natural pyrophosphate. The compound is intended to inhibit the action of cells that break down bone. It is a single-ingredient product, containing only the active Alendronate compound.

The classification as a bone resorption inhibitor defines the general therapeutic purpose of Bonemax. Alendronate works by selectively inhibiting the activity of osteoclasts, the cells responsible for dissolving and breaking down old bone tissue. This inhibitory function of Alendronate is clinically recognized for its long-term effects on the skeleton.

Available Forms: Oral Administration

Bonemax is formulated as oral pharmaceutical preparations available in two main dosage form(s): the oral tablet and the oral solution. Both forms are intended for the oral route of administration and are designed for subsequent systemic absorption via the gastrointestinal tract. The drug's preparation utilizes the active Alendronate sodium combined with stabilizing excipients in the solid oral tablet formulation, or dissolved within an aqueous vehicle for the oral solution. The availability of both forms provides flexibility for patient groups who require this chronic treatment.

Regulatory References

  1. Alendronate - NIH StatPearls

What side effects are possible with Bonemax?

Possible Side Effects and Safety Information

The safety profile for this medicine is based on official government regulatory documents, which categorize known adverse reactions and safety restrictions.

Key Adverse Reactions and Categories

Adverse reactions are classified by frequency according to regulatory standards (e.g., Very Common, Common, Rare). Key System-Organ Classes involved include Gastrointestinal disorders (e.g., nausea, vomiting, esophageal irritation) and Musculoskeletal and Connective Tissue disorders (e.g., bone, joint, and muscle pain).

Classification Examples of Reactions
Common / Expected Gastrointestinal upset, pain in muscles or joints.
Serious / Rare Atypical femoral fractures, Osteonecrosis of the Jaw (ONJ), severe esophageal reactions, and severe hypersensitivity.

Serious and Clinically Significant Safety Information

Regulatory labels highlight the risk of atypical femoral fractures (fractures of the thigh bone) that may occur with minimal or no trauma, particularly after long-term use. Osteonecrosis of the Jaw (ONJ) is another serious, documented risk involving damage to the jawbone. Patients are advised to report any new thigh, hip, or groin pain.

Safety-Related Restrictions

Official regulatory documents place restrictions on use in specific populations. The medicine is generally not recommended or contraindicated during pregnancy and breast-feeding. Caution is advised, and the drug may not be recommended for individuals with severe renal impairment (kidney function problems). A Medication Guide is required for patients to communicate these specific risks.

Exposure-Related Safety

Regulatory warnings indicate that the risk of atypical femoral fractures is linked to the duration of use, suggesting that the need for continued therapy should be periodically reviewed.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that an oral overdose of Bonemax may result in severe upper gastrointestinal adverse events and acute metabolic derangement. Documented manifestations of overdose include symptoms of upper gastrointestinal injury such as new or worsening heartburn, nausea, stomach pain, difficulty swallowing (dysphagia), and pain when swallowing (odynophagia). More severe presentations may involve signs of bleeding, such as bloody vomit or black and tarry stools. The critical systemic effects are characterized by significant drops in serum minerals, specifically Hypocalcemia and Hypophosphatemia.

Mandated Emergency Response

Immediate medical attention is required upon suspected overdose. Regulators advise contacting a local poison control center or emergency room right away. No specific antidote is known, and management is defined as symptomatic and supportive. Official instructions specify that to minimize absorption and mitigate esophageal risk, the patient should be given a full glass of milk or antacids to bind the compound. Furthermore, vomiting should not be induced, and the patient must remain fully upright. Monitoring of serum calcium and phosphate levels is required for clinical management.

Therapeutic Uses of Bonemax

Quick Facts

  • May assist in the management of osteoporosis in postmenopausal women.
  • Used for supporting bone mass in men with osteoporosis.
  • May be utilized for the care of osteoporosis related to certain glucocorticoid use.
  • May be indicated for the management of Paget's disease of bone.

What Bonemax Treats: Main Uses and Benefits

Bonemax is a medication that offers potential support in addressing several conditions where maintaining or increasing bone strength is a primary objective. The treatment is primarily indicated for the management of osteoporosis in postmenopausal women, a condition characterized by low bone mass and an increased risk of fractures. In this population, Bonemax may assist in increasing bone density and contribute to the reduction of fractures, including those of the spine and hip.

Additionally, this drug is used to support the increase of bone mass in men who have osteoporosis. It is also indicated for the care of osteoporosis that may be related to the long-term use of certain prescription medications, such as glucocorticoids, in both men and women. Furthermore, Bonemax is utilized for the management of Paget's disease of bone, a condition that involves disorganized bone growth. These usages represent the therapeutic areas where the medication may provide benefit under a healthcare provider's direction.

Eligibility and Restrictions for Use

Official Eligibility Profile for Bonemax (Teriparatide)

Eligibility for this medicine is strictly defined by regulatory documents, focusing on patient status and clinical history. The drug is contraindicated in several groups to minimize specific risks.

Populations Who Must Not Use Bonemax (Contraindications):

Contraindication Rationale (Regulatory Context)
Skeletal Malignancies History of bone cancer, bone metastases, or prior radiation therapy involving the skeleton.
Metabolic Conditions Pre-existing hypercalcemia (high blood calcium) or metabolic bone diseases other than the indicated condition (e.g., Paget's disease, primary hyperparathyroidism).
Renal Status Patients with severe renal impairment (severe kidney problems).
Age Group Pediatric and young adult patients with open epiphyses (open growth plates).

Eligibility Limitations and Restrictions:

  • Treatment Duration: The medicine has a maximum lifetime limit of 2 years; subsequent use is not recommended.
  • Reproductive Status: It must not be used during pregnancy or breastfeeding. Women of childbearing potential are required to use effective contraception during treatment.
  • Conditional Use: Patients with moderate renal impairment or a history of active or recent urolithiasis (kidney stones) require special caution during use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define two primary categories of interactions that require management constraints for this medicine. These constraints are necessary to ensure proper systemic absorption and manage the risk of gastrointestinal irritation.

Medicines and Substances that Interfere with Absorption

The absorption of Bonemax is significantly reduced when it is taken with food, beverages other than plain water, or certain other medicines. This interference can reduce the effectiveness of the product. Products and categories explicitly listed in regulatory documentation that interfere with absorption include:

  • Calcium Supplements and other mineral supplements.
  • Antacids that contain multivalent cations, such as aluminum and magnesium.
  • Other Oral Medications taken within the defined time window.
  • Beverages other than plain water, including coffee, tea, and mineral water.

To prevent this interaction, regulatory instructions state that the medicine must be taken at least 30 minutes before consuming the first food, beverage, or other oral medication of the day.

Interactions that Increase Gastrointestinal Risk

The coadministration of Bonemax with specific pain-relieving medicines carries a documented risk of potentially worsening gastrointestinal irritation. Healthcare providers are advised to use caution when co-prescribing this medicine with:

  • Aspirin
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen.

This constraint is due to the potential for a cumulative increase in adverse effects on the upper gastrointestinal mucosa.

Mechanism of Action

Targeting the Bone Resorption Cascade

Bonemax selectively targets and binds with high affinity to the hydroxyapatite mineral surface of bone. It is then internalized by the bone-dissolving cells, the osteoclasts, during the resorption process. This localized action results in the drug concentrating at bone resorption surfaces, initiating the mechanistic cascade.

Disruption of Essential Osteoclast Pathways

Inside the osteoclast, the drug functions as an enzyme inhibitor, specifically blocking Farnesyl Diphosphate Synthase (FDPS), an enzyme critical to the mevalonate pathway. This disruption prevents the formation of isoprenoid lipids required for the prenylation of vital small GTPase signaling proteins. This molecular interference leads to the collapse of the cell's cytoskeleton and the loss of function and structural integrity of the osteoclast.

Sustained Reduction in Bone Turnover

The inhibition and ultimate programmed cell death (apoptosis) of osteoclasts result in a prolonged suppression of bone resorption. This physiological consequence shifts the balance of the bone remodeling cycle, favoring bone formation over bone resorption.

Dosage and Administration Information

Bonemax (alendronate) is a bisphosphonate medication used to prevent and treat osteoporosis. Correct administration is critical to ensure proper absorption and minimize potential irritation to the esophagus.

Administration Guidelines

Action Instruction
Timing Take the tablet immediately after getting out of bed for the day, on an empty stomach.
Liquid Swallow the tablet whole with a full glass (6–8 ounces) of plain water. Do not use mineral water, coffee, tea, juice, or milk.
Position Do not lie down for at least 30 minutes after taking Bonemax. Remain fully upright (sitting, standing, or walking) and do not lie down until after you have consumed your first food of the day.
Ingestion Do not chew, crush, or suck on the tablet, as this can increase the risk of mouth or throat irritation.

Interaction and Missed Dose

Bonemax must be taken alone. After swallowing the tablet, wait at least 30 minutes before having any food, drink (other than plain water), or any other medicine, including antacids, calcium supplements, or vitamins. This is essential because food and other substances can significantly decrease the absorption of alendronate, making the medicine less effective.

If you miss a dose of the once-weekly regimen, take one tablet the morning after you remember. Do not take two tablets on the same day. Resume your usual dosing day the following week. If you are on a daily regimen, skip the missed dose and take your next tablet the following morning; do not take two doses on the same day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bonemax (Alendronate Sodium)

Evidence for Use in Postmenopausal Osteoporosis

Research has extensively explored the use of Bonemax in postmenopausal women, primarily through large-scale, controlled Randomized Controlled Trials (RCTs). These studies aimed to monitor patterns in the measured outcomes, including Bone Mineral Density (BMD) in the spine and hip, and tracked new fracture events. Studies reported measurements of BMD that, in some trials, showed values that differed from those reported for the placebo group. The findings describe how fracture events evolved in the observed populations. Research provides limited information for outcomes related to overall survival rates, and long-term effects are not fully established based only on initial RCTs.

Evidence for Use in Male Osteoporosis and Glucocorticoid-Related Bone Loss

Research for men with osteoporosis has utilized RCTs, often with modest sample sizes. Studies monitored outcomes related to systemic or functional imbalance, specifically by measuring BMD. Studies reported measurements of BMD that, in some trials, showed values that differed from those reported for the placebo group over the course of 12 months. Subgroup findings are uncertain regarding fracture patterns in men due to the smaller study sizes.

For bone loss associated with glucocorticoid (steroid) use, research examined adults taking systemic steroids. Studies generally reported that BMD measurements appeared to be maintained or increased compared to placebo. However, these follow-up durations were limited, often covering only 12 to 24 months, meaning long-term effects are not fully established for this specific population.

What Is Still Uncertain About Bonemax Evidence

The main areas where evidence is limited or certainty remains low include long-term effects beyond 5 to 10 years of use, which rely mainly on observational data. Fracture outcomes in men are less thoroughly characterized by large-scale, dedicated RCTs compared to the evidence base for postmenopausal women. The research base has limited comparative evidence directly examining Bonemax against other treatments using consistent outcome measures in all indications. Research provides context but not individual predictions.

Key Studies & References Alendronate - StatPearls - NCBI Bookshelf (NIH)

Frequently Asked Questions (FAQ)

Common questions about Bonemax (FAQ)

Q: What is Bonemax used for?

A: Bonemax is indicated for the management of the signs and symptoms of benign prostatic hyperplasia (BPH), which can include difficulty starting urination, a frequent or urgent need to urinate, and a weak urine stream. Its mechanism of action involves relaxing muscles in the prostate and bladder neck, which may help improve urine flow. The medication is typically prescribed for long-term daily use as directed by a healthcare provider.

Q: Can Bonemax cause dizziness?

A: Yes, dizziness and lightheadedness are commonly reported side effects, especially at the start of treatment or when changing dosage. This may be related to changes in blood pressure, a known effect of this class of medication.

Patients are generally advised to take care when changing position, especially when rising quickly from a seated or lying position. If lightheadedness or dizziness occurs, individuals may be advised to sit or lie down. Any persistent or concerning side effects should be discussed promptly with a prescribing healthcare professional, who can provide personalized guidance regarding treatment continuation or discontinuation.

Q: Is Bonemax a treatment for erectile dysfunction (ED)?

A: No, Bonemax is specifically indicated for BPH symptoms and is not a treatment for erectile dysfunction (ED) or a medication to improve sexual function.

Some patients taking Bonemax have reported a side effect called ejaculatory dysfunction, which can involve a decrease in the amount of semen or a condition known as retrograde ejaculation (where ejaculate goes into the bladder). Any sexual side effects should be reviewed with a healthcare provider.

How should Bonemax be stored and disposed of?

The official regulatory requirements for storing and disposing of the Bonemax (teriparatide) pen define a strict cold chain and handling profile.

Storage Requirements

Condition Requirement
Temperature Store continuously in a refrigerator, between 2 C to 8 C (36 F to 46 F). Do not freeze; a frozen pen must be discarded.
Stability Discard the pen 28 days after the first injection, even if medicine remains.
Handling Immediately return the pen to the refrigerator after each use. Store with the pen cap on and without a needle attached.
Safety Keep the pen and all needles out of the reach of children.

Disposal Instructions

Used pen needles must be removed immediately after injection and placed in an FDA-cleared, puncture-resistant sharps disposal container, following local regulations. Do not dispose of loose needles in household trash. The entire pen must be properly discarded as medical waste after the 28-day in-use period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Bonemax found in:

A-Z Index: